The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?
Saved in:
| Title: | The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors? |
|---|---|
| Authors: | van den Bent MJ; Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, The Netherlands., French PJ; Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Brat D; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Tonn JC; Department of Neurosurgery, Ludwig-Maximilians-University, Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, Germany., Touat M; Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, Paris Brain Institute, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France., Ellingson BM; UCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, USA., Young RJ; Neuroradiology Service, Department of Radiology, Memorial Sloan Kettering Cancer, New York, New York, USA., Pallud J; Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, IMA-Brain, Université Paris Cité, Paris, France.; Service de Neurochirurgie, GHU-Paris Psychiatrie et Neurosciences, Site Sainte Anne, Paris, France., von Deimling A; Department of Neuropathology, University Hospital Medicine and CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany., Sahm F; Department of Neuropathology, University Hospital Medicine and CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany., Figarella Branger D; DFB Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France., Huang RY; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Weller M; Department of Neurology & Brain Tumor Center, University Hospital Zurich & University of Zurich, Zurich, Switzerland., Mellinghoff IK; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Cloughsey TF; Department of Neurology, TC David Geffen School of Medicine at UCLA, Los Angeles, USA., Huse JT; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Aldape K; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Reifenberger G; Institute of Neuropathology, Medical Faculty, Heinrich Heine University and University Hospital Düsseldorf, and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Düsseldorf, Germany., Youssef G; Center For Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Karschnia P; German Cancer Consortium (DKTK), Partner Site Munich, Germany.; Department of Neurosurgery, Ludwig-Maximilians-University, Munich, Germany., Noushmehr H; Department of Neurosurgery, Henry Ford Hospital+Michigan State University, Detroit, Michigan, USA., Peters KB; Department of Neurosurgery, Preston Robert Tisch Brain Tumor Center, Duke University, Durham, North Carolina, USA., Ducray F; Inserm U1052, CNRS UMR5286, Université Claude Bernard Lyon, Lyon, France.; Hospices Civils de Lyon, Service de neuro-oncologie, LabEx Dev2CAN, Centre de Recherche en Cancérologie de Lyon, France., Preusser M; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria., Wen PY; Center For Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA. |
| Source: | Neuro-oncology [Neuro Oncol] 2024 Oct 03; Vol. 26 (10), pp. 1805-1822. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1523-5866 |
|---|---|
| DOI: | 10.1093/neuonc/noae107 |
